Tech Company Financing Transactions
OSE Immunotherapeutics Funding Round
On 6/20/2023, OSE Immunotherapeutics landed $1.6 million in financing from Bpifrance.
Transaction Overview
Company Name
Announced On
6/20/2023
Transaction Type
Venture Equity
Amount
$1,640,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding from Bpifrance aims at accelerating the development of an innovative companion diagnostic test based on a simple blood sample.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
22, Boulevard Benoni Goullin
Nantes, 44200
FR
Nantes, 44200
FR
Phone
Website
Email Address
Overview
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Dominique Costantini
Chairman
Maryvonne Hiance
Chief Executive Officer
Nicolas Poirier
Browse more venture capital transactions:
Prev: 6/20/2023: Adamo Foods venture capital transaction
Next: 6/20/2023: Digantara venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs